

# The TNM classification of lung tumours

Controversies in cancer staging and registration in Belgium

Dr. Mia Slabbaert

Years

### **OVERVIEW**




**Introduction: purpose of TNM-classification** 

**Usefulness of TNM – data** 

Which problems are detected by BCR and how to avoid them?



To ameliorate reporting TNM (completeness / accuracy)





# Introduction



# **INTRODUCTION – Classification systems**



#### Classification of tumours can be done

#### According to

- localisation of primary tumour
- tumourtype (histology)
- specific characteristics such as hormonal status, mutations, ....
- presence/absence/duration of symptoms
- sex of the patient
- age of the patient
- clinical assessment of the tumour (cTNM)
- histopathological assessment of the tumour (pTNM)
- ....
- → All those factors have an influence on the prognosis of the patient



# **INTRODUCTION – Purpose of TNM**



Based on the description of the ANATOMICAL EXTENT OF THE DISEASE

- to facilitate the choice of treatment
- to give an indication of the <u>prognosis</u>
- to make it possible to <u>compare treatment results</u> of different hospitals/countries
- to facilitate <u>cancer research</u>
- to sustain <u>control activities</u> (eg evaluation of quality of care : feedback reports on process and outcome indicators)



# INTRODUCTION: is registration of TNM obligatory?



21 MARCH 2003. — Royal Decree concerning standards to be met by oncological care programs to be recognised

Art. 11. § 1. Every care program (...) has to participate in cancer registration

This cancer registration contains **minimally** following parameters :

- 1) Unique patient identification (...)
- 2) Diagnosis according to International Classification and incidence date
- 3) Tumorstage (cTNM)
- 4) Conclusion of the pathological report (including pTNM);
- 5) Treatment with reference to guidelines or justification of divergence
- 6) Follow-up plan
- 7) Side effects
- 8) Survival
- 9) Date of death



# **INTRODUCTION**: general principles



**T**: extent of the primary **T**umour

N: presence/absence of regional lymph Nodes metastasis

M: presence/absence of distant Metastasis

With the 3 variables, groups are created with comparable prognosis or treatment modalities  $\rightarrow$  so called **TNM-stages** 

- cStage
- pStage / ypStage,
- BCR: combined TNM-stage (compilation of pTNM en cTNM. If both are present, pStage prevails over cStage except when clinical stage is IV)



# TNM STAGES calculated with T, N, M



T/M	Subgroup	N0	N1	N2	N3
T1	T1a	Ia	IIa	IIIa	IIIb
	T1b	Ia	IIa	IIIa	IIIb
T2	T2a	Ib	IIa	IIIa	IIIb
	T2b	IIa	IIb	IIIa	IIIb
Т3	T3 >7	IIb	IIIa	IIIa	IIIb
	T3 <sub>Inv</sub>	IIb	IIIa	IIIa	IIIb
	T3 <sub>Satell</sub>	IIb	IIIa	IIIa	IIIb
T4	T4 Inv	IIIa	IIIa	IIIb	IIIb
	T4 <sub>Ipsi Nod</sub>	IIIa	IIIa	IIIb	IIIb
M1	M1a Contra Nod	IV	IV	IV	IV
	M1a Pl Disem	IV	IV	IV	IV
	M1b	ΙV	IV	IV	IV

7<sup>th</sup> edition Lung tumours





# USEFULNESS of TNM variables/stages

#### **ILLUSTRATION OF:**

- Selection of treatment
- Composition of patient population
- Survival analysis according to T, N, M or stage
- Evaluation of Quality of Care





10

Management of Lung Cancer (NSCLC/SCLC)

#### 4.2. Treatment of NSCLC

4.2.1. Treatment of early stage NSCLC (stage cI-II and selected stage cIIIA cT3N1)

Criteria for operability

Assessment of lung function and exercise testing

Recommendations

Recommendation

Primary surgery in early stage NSCLC (stage cl-II selected stage clIIA cT3N1)

Recommendation

(Neo)adjuvant chemotherapy in early stage NSCLC (stage cl-II, selected stage IIIA cT3N1 or unforeseen N2)

Recommendation

Postoperative radiotherapy in resected early-stage NSCLC

Recommendation

# Multidisciplinair oncologisch handboek

#### MARIA MIDDELARES

2e editie 2010

#### STADIUM IIIa:


- \* T3N1M0: heelkundige resectie

  (indien medisch inoperabel: radiotherapie met curatieve intentie).

  Postoperatieve chemotherapie wordt aan patiënt voorgesteld.
- \* T1-3N2M2, na bewezen mediastinoscopie of EBUS, niet massieve klieren:
  Inductiechemotherapie
  dan radiotherapie indien stabiele ziekte of progressieve ziekte, tenzij minimale N2, dan evt.heelkunde.
- \* T4N0-1M0: indien chirurgisch resecabel:
  Heelkunde,
  anders concomitante chemotherapie overwegen.


#### STADIUM IIIB

- \* T4N2M0: indien fitte patiënt: Concomitante radiochemotherapie, zo niet: inductiechemo, dan radiotherapie.
- Telke N3M0: overweeg concomitante radiochemotherapie (indien fitte patiënt), anders 'palliatieve' chemotherapie.
- STADIUM IV: T elke N elke M1
  - Indien symptomatische hersenmeta: eerst bestralen, als dan algemene toestand in orde is: palliatieve chemotherapie.
  - \* Indien andere meta: palliatieve chemotherapie, eventueel combinatie met radiotherapie op meta.



Different patient-population in different hospitals






Cases from 45 sources in 20 countries 1990-2000








Chest. 2009;136(1):260-271. doi:10.1378/chest.08-0978

Cases from 45 sources in 20 countries 1990-2000








Chest. 2009;136(1):260-271. doi:10.1378/chest.08-0978
Cases from 45 sources in 20 countries 1990-2000





# FIGURE 71 - LUNG CANCER: RELATIVE SURVIVAL BY STAGE IN FEMALES (BELGIUM, 2004-2008)









Federaal Kenniscentrum voor de Gezondheidszorg Centre Fédéral d'Expertise des Soins de Santé Belgian Health Care Knowledge Centre

# Quality indicators for the diagnosis and treatment of lung cancer

FRANCE VRIJENS, LEEN VERLEYE, CINDY DE GENDT\*, VIKI SCHILLEMANS\*, JO ROBAYS, CÉCILE CAMBERLIN, CÉCILE DUBOIS, SABINE STORDEUR, DAVID JEGOU\*, GEERT SILVERSMIT\*, ELIZABETH VAN EYCKEN\*, ISABELLE WAUTERS,

JAN P VAN MEERBEECK

\* BELGIAN CANCER REGISTRY

2016. KCE Reports 266Cs. D/2016/10.273/38.




Quality of data reporting to BCR (1)

# Results

- Room for improvement:
  - Reporting to Belgian Cancer Registry suboptimal (e.g. 23% clinical stage missing)

Distribution of clinical stage (incidence 2010-2011)




2016. KCE Reports 266Cs. D/2016/10.273/38.
Part of figure 23

# **GOOD NEWS: Clinical stage availability**









# GOOD NEWS: availability of stage information



By adding "stage by source" to 'stage calculated by BCR'

Field for 'other classifications' or 'remark'

topo	histo /3	inc year	сТ	cN	cM	рТ	pΝ	рМ	cStage by BCR	pStage by BCR	COMBstage by BCR	Stage by source	
349	8000	2014	NS	NS	NS	NS	NS	NS	Х	Х	Х	IV	
349	8041	2014	NS	NS	NS	NS	NS	NS	Х	Х	X	IV	
341	8041	2014	NS	NS	NS	NS	NS	NS	X	Х	X	IV	
343	8140	2014	х	0	х	NS	NS	NS	X	Х	Х	IV	
349	8041	2014	NS	NS	NS	NS	NS	NS	X	Х	X	IV	
343	8481	2014	NS	NS	NS	NS	NS	NS	X	Х	Х	IV	
341	8140	2014	NS	NS	NS	NS	NS	NS	Х	Х	Х	IIIB	
343	8041	2014	NS	NS	NS	NS	NS	NS	Х	Х	Х	IV	



# **GOOD NEWS:** availability of stage information





topo	lat	histo	behaviour	cT	cN	cM	рТ	pΝ	pM	other classification:stage
C34.0	2	8012	3	4	2	1b				
C34.0	2	8070	3	4	2	1b				4
C34.1	1	8140	3	2a	0	0				
C34.1	1	8041	3	4	3	1a				IV
C34.1	1	8140	3	1b	1	1b				4
C34.1	2	8140	3	2a	0	1b				4
C34.1	1	8140	3	3	2	1b				
C34.1	2	8140	3	3	0	Х				IV
C34.1	1	8070	3	1a	2	Х				
C34.1	1	8070	3	3	0	Х				
C34.1	1	8140	3							4
C34.1	2	8070	3							IIA
C34.1	2	8550	3				1a	0	Х	
C34.1	2	8140	3				1a	0	х	
C34.1	2	8140	3				2a	0	1b	

Stage IV  $\rightarrow$  any T, any N, M1 Stage IIA  $\rightarrow$  T2b N0 M0 or T1a/b N1 M0 or T2a N1 M0

<u>Clinical</u> stage or <u>pathological</u> stage?



Inc year 2014: **LUNG TUMOURS** (stageable)

Missing comb stage

CIB2014 with stages calculated by **BCR** 


860 (10 %)

% really missing stages TNM stage by source

after adding

790 (9,3 %)








#### Room for improvement:

 Reporting to Belgian Cancer Registry suboptimal (e.g. 23% clinical stage missing)

Added stages						
Stage I	5					
Stage III	9					
Stage IV	56					









# 1) No TNM variables



topo	lat	histo	behaviour	cT	cN	cM	рТ	pΝ	рМ
C34.0	2	8012	3	4	2	1b			
C34.0	2	8070	3	4	2	1b			
C34.0	1	8140	3	4	0	1b			
C34.1	2	8550	3				3	1	х
C34.1	2	8140	3	4	0	0			
C34.1	1	8140	3	2a	0	0			
C34.1	1	8041	3	4	3	1a			
C34.1	1	8140	3	1b	1	1b			
C34.1	2	8140	3	2a	0	1b			
C34.1	1	8140	3	3	2	1b			
C34.1	2	8140	3	3	0	х			
C34.1	1	8070	3	1a	2	х			
C34.1	1	8070	3	3	0	х			
C34.1	1	8140	3						
C34.1	2	8070	3						
C34.1	2	8550	3				1a	0	х
C34.1	2	8140	3				1a	0	х
C34.1	2	8140	3				2a	0	1b
C34.1	2	8140	3				2a	0	х
C34.1	1	8550	3				2b	2	х
C34.1	1	8140	3	4	3	1b			
C34.1	2	8070	3				3	0	х
C34.1	1	8140	3	1a	0	1a			
C34.1	2	8140	3	1b	3	1b			
C34.1	2	8140	3	4	3	1b			





# 1) No TNM variables

#### **Problems:**

- How to calculate QI (treatment following guidelines based on stage)?
- How to know your patient population?
- How to interpret survival results?

#### **Solution:**

- wait until staging examinations are done
- wait until surgery is executed and AP-report is available
- in case of referral to other centre: please mention!
- ask a question in case of difficulties to assign a TNM











# 2) No cTNM when pTNM is present



topo	lat	histo	behaviour	cT	cN	cM	рТ	pΝ	pМ
C34.0	2	8012	3	4	2	1b			
C34.0	2	8070	3	4	2	1b			
C34.0	1	8140	3	4	0	1b			
C34.1	2	8550	3				3	1	х
C34.1	2	8140	3	4	0	0			
C34.1	1	8140	3	2a	0	0			
C34.1	1	8140	3	3	2	1b			
C34.1	1	8140	3	1a	0	0			
C34.1	1	8140	3	1b	0	0			
C34.1	1	8140	3	2a	0	0			
C34.1	2	8140	3	3	0	х			
C34.1	1	8070	3	1a	2	х			
C34.1	1	8070	3	3	0	х			
C34.1	1	8140	3						
C34.1	2	8070	3						
C34.1	2	8550	3				1a	0	х
C34.1	1	8550	3				2b	2	х
C34.1	1	8140	3	4	3	1b			
C34.1	2	8070	3				3	0	х
C34.1	1	8140	3	1a	0	1a			
C34.1	2	8140	3	4	3	1b			





# 2) No cTNM when pTNM is present

#### **Both are important!**

- cTNM will help do decide if surgery is indicated (→ Quality Indicators)
- pTNM will help to decide if adjuvant treatment is necessary and gives more accurate prognostic information
- cTNM maybe different from pTNM preop <u>under</u>staging preop <u>over</u>staging ...



if cTNM = pTNM ... 'rather suspicious' for







# 3) No pTNM in case of surgical resection of primary tumour

topo	lat	histo	behaviour	cT	cN	cM	рТ	pΝ	pМ	treatment (done or planned)
C34.0	2	8012	3	4	2	1b				
C34.0	2	8070	3	4	2	1b				
C34.0	1	8140	3	4	0	1b				
C34.1	2	8550	3				3	1	Х	
C34.1	2	8140	3	4	0	0				
C34.1	1	8140	3	2a	0	0				
C34.1	1	8140	3	3	2	1b				
C34.1	1	8140	3	1a	0	0				10
C34.1	1	8140	3	1b	0	0				10
C34.1	1	8140	3	2a	0	0				10
C34.1	2	8140	3	3	0	Х				
C34.1	1	8070	3	1a	2	Х				
C34.1	1	8070	3	3	0	Х				
C34.1	1	8140	3							
C34.1	2	8070	3							
C34.1	2	8550	3				1a	0	Х	
C34.1	1	8550	3				2b	2	Х	
C34.1	1	8140	3	4	3	1b				
C34.1	2	8070	3				3	0	Х	
C34.1	1	8140	3	1a	0	1a				
C34.1	2	8140	3	4	3	1b				





# 3) No pTNM in case of surgical resection of primary tumour

#### **Solution:**

- wait until surgery is executed and AP-report is available
- in case of referral to other centre: please mention!
- use "10" in correct manner: only for surgery of the primary tumour, not for staging surgical procedures (mediastinoscopy, thoracoscopy, lymph node removal,...): surgical staging is part of clinical staging!





# 4) Presence of pTNM without evidence of surgical procedure is (rarely) possible

pT = only possible after resection of the primary tumour OR a biopsy allowing to evaluate the highest T-category

eg : CT-scan : lung tumour possibly invading oesophagus
Biopsy of nodule in oesophagus = ingrowth of lung tumour

→ cT4

Even when no surgery → pT4 can be registered because of microscopic proof of the highest pT category





# 5) pN without pT

#### Information about lymph nodes obtained by

- physical examination
- imaging
- endoscopy (EBUS/EUS)
- mediastinoscopy, mediastinotomy, thoracoscopy, surgical exploration,...



#### And no further surgical intervention on primary tumour



#### 7<sup>th</sup> edition of TNM, page 8:

An excisional biopsy of a lymph node without pathological assessment of the primary is insufficient to fully evaluate the pN category and is a clinical classification, in other words: no pN without pT.

Thus, in this cases cN should be used.





# 








# 7) Wrong TNM-variables


- Not existing values (eg T3a, T4b,...)
- Wrong choice of value



years
Belgian Cancer Registry

 PANCOAST tumour: tumour in the apex of the lung = tumour located in the sulcus superior, with destructive lesions and involvement of brachial plexus and cervical sympathetic nerves → at least cT3 (regardless of diameter of the tumour)







Chest X-ray

CT Scan




#### Do not forget ATELECTASIS OR OBSTRUCTIVE PNEUMONITIS!

Regardless diameter of lung tumour:

#### In 7th edition:

- atelectasis/pneumonitis extending to the hilus but not involving entire lung
  - → at least cT2/pT2
- atelectasis/pneumonitis involving entire lung
  - $\rightarrow$  at least cT3/pT3 (changed in 8<sup>th</sup> edition  $\rightarrow$  also T2)







- Be careful with SYNCHRONOUS BILATERAL LESIONS!
  - 1) Bilateral lesions with PROVEN same histology
    - → 1 tumour in a metastatic setting
    - → at least cM1a AND pM1a
  - 2) Bilateral lesions but histology of one or both lesions unknown
    - → considered to be the same histology
    - → 1 tumour in a metastatic setting
    - → at least cM1a
  - 3) Bilateral lesions but PROVEN different histology (histological FAMILY)
    - → 2 primary tumours
    - → each with own TNM stage

**VERY IMPORTANT IMPLICATIONS FOR TREATMENT / PROGNOSIS** 





- Make a clear difference between NEW LESIONS AND RECURRENT LESIONS
  - 1) New lesion in lung after previous one and PROVEN same histology (regardless laterality)
    - → 1 tumour with recurrent lesion (no New Diagnosis)
    - → maybe rTNM (not asked by BCR)
  - 2) New lesion in lung after previous one and PROVEN ≠ histology (regardless laterality)
    - → New Diagnosis
  - 3) New lesion in lung after previous one and no histology available (regardless laterality)
    - → histology considered to be the same
    - → 1 tumour with recurrent lesion (no New Diagnosis)
    - → maybe rTNM (not asked by BCR)
- Make a clear difference between METASTASIS IN LYMPH NODES (REGIONAL → N) AND
   AT A DISTANCE (non-regional LN included → M) Eg. metastatic ipsilat hilar LN = N1, not M1





# TNM: a fascinating but never ending story.....







#### **CASE 1:**



#### CT-scan:

- Tumour of 2,5 cm in upper lobe of right lung + nodule of 1 cm in lower lobe of right lung
- Enlarged mediastinal lymph nodes
- No other lesions observed
- → Bronchoscopy + biopsy of nodule in upper lobe
- → EUS : punction of ipsilateral mediastinal lymph nodes

APO lung biopsy: adenocarcinoma

APO EUS: compatible with metastasized adenoca of lung

### How to stage this tumour?

- 1) cT1N2M1
- 2)  $cT4NxM0 + pT_N2M_$
- 3) cT4N2M0
- 4)  $cT4N2M1 + pT_N_M1$

#### **ANSWER TO CASE 1:**



#### CT-scan:

- Tumour of 2,5 cm in upper lobe of right lung + nodule of 1 cm in lower lobe of right lung  $\rightarrow$  cT4 (no pT4 since no microscopic proof of second nodule)
- Enlarged mediastinal lymph nodes
- No other lesions observed → cM0
- → Bronchoscopy + biopsy of nodule in upper lobe
- → EUS : punction of ipsilateral mediastinal lymph nodes

APO lung biopsy: adenocarcinoma

APO EUS: compatible with metastasized adenoca of lung  $\rightarrow$  cN2 (regional <u>node</u> metastasis)

How to stage this tumour?

- 1) cT1N2M1 (wrong: no metastasis at a distance)
- 2) cT4NxM0 + pT\_N2M\_ (wrong : EUS provides information for clinical staging)
- *3) cT4N2M0* = *correct*
- 4) cT4N2M1 + pT\_N\_M1 (wrong = no proof of distant metastasis)

#### **CASE 2:**

#### CT-scan:

- Pneumonitis of left upper lobe due to obstruction by tumour of 2,5 cm
- Enlarged mediastinal lymph nodes
- No other lesions observed
- → Bronchoscopy + biopsy of tumour : APO : spinocellular carcinoma
- → Mediastinoscopy: biopsy of multiple LN

  APO: 1 node paratracheal right positive for meta of spinocellular ca

#### How to stage this tumour?

- 1) cT1N0M1
- 2) cT2N2M0
- 3) cT1N3M0
- 4) cT2N3M0



#### **Answer to CASE 2:**

#### CT-scan:

- Pneumonitis of left upper lobe due to obstruction by tumour of 2,5 cm
- Enlarged mediastinal lymph nodes → at least cT2, regardless 2.5 cm
- No other lesions observed → M0
- → Bronchoscopy + biopsy of tumour : APO : spinocellular carcinoma
- → Mediastinoscopy : biopsy of multiple LN

APO: 1 node paratracheal right positive for meta of spinocellular ca

### How to stage this tumour?

- 1) cT1N0M1 (wrong: pneumonitis overrules size; no distant metastasis)
- 2) cT2N2M0 (N3 because of contralateral mediastinal)
- 3) cT1N3M0 (wrong: pneumonitis overrules size)
- 4) cT2N3M0 (in the TNM 8<sup>th</sup> edition cT2aN3M0)



= contralateral mediastinal